North Run Capital, LP Maxcyte, Inc. Transaction History
North Run Capital, LP
- $43 Million
- Q4 2022
A detailed history of North Run Capital, LP transactions in Maxcyte, Inc. stock. As of the latest transaction made, North Run Capital, LP holds 451,960 shares of MXCT stock, worth $1.7 Million. This represents 5.73% of its overall portfolio holdings.
Number of Shares
451,960
Previous 556,960
18.85%
Holding current value
$1.7 Million
Previous $3.62 Million
31.85%
% of portfolio
5.73%
Previous 7.35%
Shares
2 transactions
Others Institutions Holding MXCT
# of Institutions
118Shares Held
65MCall Options Held
600Put Options Held
2.7K-
Black Rock Inc. New York, NY8.14MShares$30.7 Million0.0% of portfolio
-
Cadian Capital Management, LP New York, NY7.62MShares$28.7 Million1.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.65MShares$21.3 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.18MShares$19.5 Million0.01% of portfolio
-
Vitruvian Partners LLP5.04MShares$19 Million5.8% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $383M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...